###begin article-title 0
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 37 53 37 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 37 53 <span type="species:ncbi:5476">Candida albicans</span>
Serum repressing efflux pump CDR1 in Candida albicans
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 252 268 252 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 510 515 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 527 538 527 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 252 268 <span type="species:ncbi:5476">Candida albicans</span>
###xml 326 331 <span type="species:ncbi:9606">human</span>
###xml 527 538 <span type="species:ncbi:5476">C. albicans</span>
In the past decades, the prevalence of candidemia has increased significantly and drug resistance has also become a pressing problem. Overexpression of CDR1, an efflux pump, has been proposed as a major mechanism contributing to the drug resistance in Candida albicans. It has been demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics. The aim of this study is to understand the effects of serum in drug susceptibility via monitoring the activity of CDR1 promoter of C. albicans.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 14 26 14 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 53 63 53 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 273 283 273 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC</italic>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 342 353 342 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 386 397 386 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 492 497 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 14 25 <span type="species:ncbi:5476">C. albicans</span>
###xml 342 353 <span type="species:ncbi:5476">C. albicans</span>
The wild-type C. albicans cells (SC5314) but not the cdr1/cdr1 mutant cells became more susceptible to the antifungal drug when the medium contained serum. To understand the regulation of CDR1 in the presence of serum, we have constructed CDR1 promoter-Renilla luciferase (CDR1p-RLUC) reporter to monitor the activity of the CDR1 promoter in C. albicans. As expected, the expression of CDR1p-RLUC was induced by miconazole. Surprisingly, it was repressed by serum. Consistently, the level of CDR1 mRNA was also reduced in the presence of serum but not N-acetyl-D-glucosamine, a known inducer for germ tube formation.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 139 151 139 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 242 250 242 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 317 326 317 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 139 150 <span type="species:ncbi:5476">C. albicans</span>
Our finding that the expression of CDR1 is repressed by serum raises the question as to how does CDR1 contribute to the drug resistance in C. albicans causing candidemia. This also suggests that it is important to re-assess the prediction of in vivo therapeutic outcome of candidemia based on the results of standard in vitro antifungal susceptibility testing, conducted in the absence of serum.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 91 108 91 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 91 107 <span type="species:ncbi:5476">Candida albicans</span>
###xml 159 165 <span type="species:ncbi:9606">humans</span>
In the past decades, the prevalence of candidemia has increased significantly. Among them, Candida albicans is the most frequently isolated fungal pathogen in humans and has caused morbidity in seriously debilitated and immunocompromised hosts. Coinciding with the increased usage of antifungal drugs, the incidences of drug resistance have also increased [1,2].
###end p 9
###begin p 10
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 179 191 179 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 384 396 384 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 476 490 476 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catup1/Catup1 </italic>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 658 666 658 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CaNDT80 </italic>
###xml 670 676 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CaTAC1</italic>
###xml 725 730 725 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 733 745 733 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 746 747 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 748 749 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 179 190 <span type="species:ncbi:5476">C. albicans</span>
###xml 384 395 <span type="species:ncbi:5476">C. albicans</span>
###xml 733 744 <span type="species:ncbi:5476">C. albicans</span>
Overexpression of CDR1, an ATP binding cassette (ABC) transporter, has been shown to be the major mechanism for the drug resistance of clinical isolates [3]. Mutations on CDR1 in C. albicans have resulted in an increased susceptibility to azole drugs [4], which is consistent with the observation that overexpression of CDR1 contributes to the drug resistance of clinical isolates of C. albicans [5]. Interestingly, the expression of CDR1 is increased approximately 4-fold in Catup1/Catup1 mutant cells, which are predominately in the hyphal form [6]. This data suggests that CaTup1 acts as a negative regulator of CDR1. Recently, two transcription factors, CaNDT80 and CaTAC1, have been identified as positive regulators of CDR1 in C. albicans [7,8].
###end p 10
###begin p 11
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 163 175 163 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 370 380 370 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 624 634 624 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC</italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 689 701 689 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 816 820 816 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 163 174 <span type="species:ncbi:5476">C. albicans</span>
###xml 689 700 <span type="species:ncbi:5476">C. albicans</span>
Previous works have demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics [9]. During an infection, the C. albicans cells exist in the host body and are surrounded by blood and other body fluid, where they encounter the antifungal drugs. In this study, we have found that the wild-type SC5314 cells but not the cdr1/cdr1 mutant cells became more susceptible to fluconazole, a commonly used antifungal drug, when the medium contained serum. To investigate the regulation of CDR1 in the presence of serum, we have constructed a CDR1 promoter-Renilla luciferase gene (CDR1p-RLUC) reporter to monitor the activity of CDR1 promoter in C. albicans under different conditions. In conclusion, serum increases the drug susceptibility by repressing the expression of CDR1.
###end p 11
###begin title 12
Results and discussion
###end title 12
###begin p 13
###xml 67 78 67 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 268 278 268 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 595 605 595 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 751 756 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 807 808 807 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 67 78 <span type="species:ncbi:5476">C. albicans</span>
###xml 222 228 <span type="species:ncbi:9913">bovine</span>
To determine if serum has any effect on the drug susceptibility of C. albicans, we have determined the growth of cells in the presence of different concentrations of fluconazole and in the absence or presence of 10% fetal bovine serum. The wild-type cells but not the cdr1/cdr1 mutant cells became more susceptible to fluconazole when the medium contained serum (Fig. 1). The growth of the wild-type cells was less inhibited by 0.125 mg/l fluconazole in serum-free medium than that in serum-containing one (vertical dotted line). The minimum inhibitory concentration (MIC) of fluconazole of the cdr1/cdr1 mutant cells (0.0625 mg/l) was lower than that of the wild-type cells (0.25 mg/l). This is consistent with the previous reports that mutations on CDR1 have resulted in an increased drug susceptibility [4,7]. The MIC of fluconazole of the wild-type cells was 2-fold lower in serum-containing medium than that in serum-free one (0.125 mg/l vs. 0.25 mg/l).
###end p 13
###begin p 14
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 180 190 180 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 371 382 371 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 578 590 578 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 607 618 607 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 791 802 785 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 855 856 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 960 965 954 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 991 993 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1034 1045 1028 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 1073 1078 1067 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 578 589 <span type="species:ncbi:5476">C. albicans</span>
It is generally accepted that overexpression of CDR1 is the major mechanism for the drug resistance of clinical isolates [3,5,10]. Our finding that the wild-type cells but not the cdr1/cdr1 mutants became more susceptible to fluconazole in serum-containing medium led us to further investigate the effects of serum on CDR1 expression. First of all, we have constructed a CDR1p-RLUC reporter (Fig. 2). The construct was integrated into the CDR1 locus and its activities under different conditions in different strains were determined. The results are summarized in Figure 3. The C. albicans cells containing CDR1p-RLUC were harvested after being grown in Synthetic Dextrose (SD) liquid medium in the absence or presence of 100 mg/l of miconazole at 35degreesC for one hour. The expression of CDR1p-RLUC was induced approximately 2-fold by miconazole (Fig. 3, comparing bar 1 to bar 2). This datum is consistent with the previously report that the expression of CDR1 is induced by miconazole [11] and also suggests that the activity of CDR1p-RLUC can refer the expression of CDR1 under our experimental setup.
###end p 14
###begin p 15
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 95 106 95 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 109 121 109 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 296 306 290 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC</italic>
###xml 356 367 350 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 428 429 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 698 709 692 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 715 716 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 109 120 <span type="species:ncbi:5476">C. albicans</span>
###xml 203 209 <span type="species:ncbi:9913">bovine</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
###xml 567 572 <span type="species:ncbi:9606">human</span>
###xml 638 644 <span type="species:ncbi:9913">bovine</span>
###xml 656 661 <span type="species:ncbi:9606">human</span>
To determine the effect of serum on the expression of CDR1, we have measured the activities of CDR1p-RLUC in C. albicans cells that were grown in SD liquid medium in the absence or presence of 10% fetal bovine serum at 35degreesC for one hour. Surprisingly, the serum repressed the expression of CDR1p-RLUC. In the presence of the serum, the expression of CDR1p-RLUC was reduced to 50% of that in the absence of the serum (Fig. 3, comparing bar 1 to bar 3). To determine if human serum also has the same effect, we have also cultured the cells in the presence of 10% human serum from two healthy volunteers. Interestingly, like the fetal bovine serum, the human sera also reduced the expression of CDR1p-RLUC (Fig. 3, comparing bar 1 to bars 4 and 5).
###end p 15
###begin p 16
###xml 44 55 44 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 142 154 142 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 558 568 558 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC</italic>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 693 704 693 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 978 990 978 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1097 1102 1097 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 1108 1109 1108 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1183 1188 1183 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 1308 1313 1308 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 1329 1343 1329 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catup1/Catup1 </italic>
###xml 1397 1398 1397 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 142 153 <span type="species:ncbi:5476">C. albicans</span>
###xml 338 344 <span type="species:ncbi:9913">bovine</span>
###xml 693 704 <span type="species:ncbi:5476">C. albicans</span>
###xml 978 989 <span type="species:ncbi:5476">C. albicans</span>
This datum suggests that if the activity of CDR1p-RLUC echoes the expression of endogenous CDR1, the level of CDR1 mRNA would be reduced when C. albicans cells were grown in the presence of serum. To investigate this hypothesis, we have measured the level of CDR1 mRNAs in different strains by real-time PCR. In the presence of 10% fetal bovine serum, the level of CDR1 mRNA in the wild-type cells was reduced to approximately 50% of that in the absence of the serum (Fig. 4, comparing bar 1 to bar 2), which re-assured the result of the activity assay with CDR1p-RLUC. These results conclude that serum represses the expression of CDR1. Since serum is a key stimulant for hyphal formation of C. albicans, we would like to determine whether its effect on CDR1 expression is due to a factor solely present in serum or common in other hypha-inducing media also. Consequently, we have determined if 5 mM N-acetyl-D-glucosamine (Glu-NAc), a known inducer for germ tube formation of C. albicans would alter the expression of CDR1 [12,13]. Unlike serum, Glu-NAc did not have effect on the expression of CDR1 (Fig. 4, comparing bar 1 and bar 3). This result suggests that the expression of CDR1 is not repressed by every hypha-inducing medium. This is consistent with the previously reported that the expression of CDR1 is increased in Catup1/Catup1 mutant cells, which are predominately in hyphal form [6].
###end p 16
###begin p 17
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 73 85 73 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 205 221 205 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80 </italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 298 306 298 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CaNDT80 </italic>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 551 567 551 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80 </italic>
###xml 766 771 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 778 794 778 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80 </italic>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 73 84 <span type="species:ncbi:5476">C. albicans</span>
###xml 719 725 <span type="species:ncbi:9913">bovine</span>
Recently, CaNdt80 has been identified as a positive regulator of CDR1 in C. albicans [7]. To investigate if serum represses the expression of CDR1 via CaNdt80, we have also determined the level of CDR1 in Candt80/Candt80 mutant cells. The expression of CDR1 was reduced 50% by the null mutation of CaNDT80 (Fig. 4, comparing bar 1 to bar 4), which is consistent with our previous finding that CaNdt80 regulates CDR1 positively [7]. If regulating the expression of CDR1 by serum is independent of the activity of CaNdt80, the level of CDR1 mRNA in the Candt80/Candt80 mutant cells would be significantly reduced in the presence of serum. Otherwise, it will not (if there is any). Our data showed that although 10% fetal bovine serum further reduced the expression of CDR1 in the Candt80/Candt80 mutant cells, the effect was mild (Fig. 4, comparing bar 4 to bar 5).
###end p 17
###begin title 18
Conclusion
###end title 18
###begin p 19
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 309 325 309 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80 </italic>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
We have found that the wild-type cells became more susceptible to fluconazole when the medium contained serum. Furthermore, the expression of CDR1 is repressed significantly by serum according to the activity of the reporter and CDR1 mRNA level. The level of CDR1 mRNA was only mildly reduced by serum in the Candt80/Candt80 mutant cells suggesting the major, if not the sole, regulatory ability of serum may be through the activity of CaNdt80. However, we still can not rule out the possibility that serum may also act through Tac1 and/or other unidentified regulators. It will be interesting to investigate the coordination between CaNdt80 and Tac1 in regulating the expression of CDR1 in the presence of serum.
###end p 19
###begin p 20
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 304 312 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 316 325 316 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
The standard antifungal susceptibility testing [14], which is conducted in the absence of serum, is unreliable in predicting the clinical outcome of therapies, especially for systemic infections. Our finding may explain the existence and persistence of such a discrepancy between the susceptibilities of in vivo and in vitro environments.
###end p 20
###begin title 21
Methods
###end title 21
###begin title 22
Strains and media
###end title 22
###begin p 23
###xml 11 23 11 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 123 129 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 130 134 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 148 154 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 164 168 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 183 189 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 190 194 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 208 246 172 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434 cdr1::hisG/cdr1::hisG-URA3-hisG</italic>
###xml 277 278 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 289 293 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 307 313 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 314 318 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 332 458 278 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80::URA3-dpl20 ENO1/eno1::ENO1-tetR-SCHAP4-3xHA-HIS1</italic>
###xml 472 476 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 490 496 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 497 501 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 515 622 443 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80:: URA3-dpl200:: CaNDT80::HIS1 </italic>
###xml 623 624 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 11 22 <span type="species:ncbi:5476">C. albicans</span>
###xml 627 632 <span type="species:ncbi:4932">Yeast</span>
###xml 669 674 <span type="species:ncbi:4932">yeast</span>
###xml 756 761 <span type="species:ncbi:4932">yeast</span>
Strains of C. albicans used in this studyare as following: SC5314, the wild-type control strain; DSY448, ura3Delta:: lambdaimm434/ura3Delta:: lambdaimm434; DSY448, ura3Delta:: lambda imm434/ura3Delta:: lambdaimm434 cdr1::hisG/cdr1::hisG-URA3-hisG, a gift from Dr. D. Sanglard [4]; YLO133, ura3Delta:: lambdaimm434/ura3Delta:: lambdaimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80::URA3-dpl20 ENO1/eno1::ENO1-tetR-SCHAP4-3xHA-HIS1; and YLO137, ura3Delta:: lambdaimm434/ura3Delta:: lambdaimm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG Candt80::GFP-Arg4/Candt80:: URA3-dpl200:: CaNDT80::HIS1 [7]. Yeast Peptone Dextrose (YPD) contained 1% yeast extract, 2% peptone, and 2% dextrose and Synthetic Dextrose (SD) contained 0.67% yeast nitrogen base without amino acid and 2% dextrose. All agar plates were prepared with addition of 2% agar in media.
###end p 23
###begin title 24
Antifungal drug susceptibility
###end title 24
###begin p 25
###xml 91 100 91 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
The minimum inhibitory concentration (MIC) to fluconazole of each strain was determined by in vitro antifungal susceptibility testing using microdilution method according to published guidelines by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) [14]. The antifungal agent fluconazole (Pfizer, Inc.) was freshly prepared as a stock at the concentration of 16 g/l in DMSO. For working concentration, (16~0.0312 mug/ml), it was processed by stepwise twofold dilutions in SD medium. A drug-free culture and a sterile control were included in each microtitre plate. The optical density (OD) in each well of the microtitre plate was read with a microplate reader (Molecular Devices, SPECTRA MAX plus) at 600 nm after incubated at 35degreesC for 48 hours. The drug inhibitory curve was presented by the OD of each well with different concentrations of fluconazole relative to the OD of the drug-free control. The MIC was defined as the lowest concentration which reduced the culture broth turbidity by 50%.
###end p 25
###begin title 26
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
Construction of CDR1 promoter-Renilla luciferase
###end title 26
###begin p 27
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RLUC </italic>
###xml 77 89 77 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WH11 </italic>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RLUC </italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 242 245 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">URA </italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nae</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 542 558 542 558 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ATCGATACTCAATAAG</underline>
###xml 718 721 718 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cla</italic>
###xml 727 730 727 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xma</italic>
###xml 738 739 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 786 789 786 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 865 870 865 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 950 955 950 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 982 984 982 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1006 1010 1006 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 1024 1030 1015 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434</italic>
###xml 1031 1035 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ura3</italic>
###xml 1049 1072 1031 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imm434 CDR1p-RLUC-URA3 </italic>
###xml 1078 1079 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 77 88 <span type="species:ncbi:5476">C. albicans</span>
A 1.2 kilo-base-pair (kb) DNA fragment containing the RLUC gene modified for C. albicans with the WH11 transcription termination sequence at the 3' end of the RLUC open reading frame was isolated from pCRW3 [11] after digested with EcoRV and NcoI. The purified DNA fragment was blunt-ended with klenow and then ligated to the pGEM-URA [15] at the NaeI site to construct the plasmid LOB60. Another 1.2 kb DNA fragment containing the promoter and the translation initiation site of CDR1 was generated by using oligonucleotides HJL340, 5'-d(GATCATCGATACTCAATAAG) and HJL 341, 5'-d(CGCAAGCCCGGGTAATTTTTTTC). The plasmid LOB60 was then used to construct plasmid LOB85 by introducing the PCR product at restriction sites of ClaI and XmaI (Fig. 2). The resulted LOB85 was then linearized with EcoRV at the 455 base-pair (bp) upstream of the translation initiation site of CDR1 and used for transformation to integrate into the chromosome at the promoter of CDR1 of CAI4 to produce the Ura3+ transformant, YLO185, ura3Delta:: lambdaimm434/ura3Delta:: lambdaimm434 CDR1p-RLUC-URA3 (Fig. 2).
###end p 27
###begin title 28
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 57 67 57 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC</italic>
Activity assay of CDR1 promoter-Renilla luciferase gene (CDR1p-RLUC)
###end title 28
###begin p 29
###xml 23 35 23 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 52 63 52 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
###xml 146 148 146 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 23 34 <span type="species:ncbi:5476">C. albicans</span>
###xml 336 342 <span type="species:ncbi:9913">bovine</span>
###xml 395 400 <span type="species:ncbi:9606">human</span>
Overnight pre-cultured C. albicans cells containing CDR1p-RLUC were diluted in 10 ml of the SD liquid medium to a final concentration about 4 x 106 cells per ml. Prior to the addition of serum or miconazole, the dilutents were incubated at 30degreesC for 4 hours. The cells were harvested after treated with 10% serum (either the fetal bovine serum provided by JRH Biosciences, Australia or the human serum from two coauthors) or 100 mug/ml of miconazole (Sigma M-3512) at 35degreesC for one hour. The control cells were grown in SD medium in the absence of serum and miconazole at 35degreesC for one hour. The cells were resuspended in lysis buffer for luciferase assay using the Dual-Glo Luciferase Assay System (E2940, Promega, Madison, USA). The activity of luciferase was determined according to the protocol provided by the manufacturer. The activity of luciferase in the control cells without treatment was defined as one and the relative activity of luciferase in cells with other treatments was normalized accordingly.
###end p 29
###begin title 30
Quantitative analysis of the mRNA level by Real-Time PCR
###end title 30
###begin p 31
###xml 4 16 4 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans </italic>
###xml 45 49 45 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600 </sub>
###xml 430 433 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 699 704 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEF3 </italic>
###xml 858 860 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 876 881 841 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 4 15 <span type="species:ncbi:5476">C. albicans</span>
###xml 160 166 <span type="species:ncbi:9913">bovine</span>
The C. albicans cells were harvested at an OD600 between 0.7 and 0.9 after being grown in 20 ml of the SD liquid medium in the absence or presence of 10% fetal bovine serum (JRH Biosciences, Australia) or 5 mM Glu-NAc (Sigma, A8625) at 37degreesC for one hour. A real-time PCR was performed in a Rotor-Genetrade mark 3000 instrument (Corbett Research, Australia) with a TITANIUMtrade mark Taq PCR kit (BD Clontech 639210) and SYBR(R)Green I Nucleic Acid Stain (Cambrex 50513) to determine the level of mRNA. The sample was automatically setup by CAS-1200trade mark (Corbett Research, Australia). The real-time PCR was performed according to the instructions from the manufacturer. The expression of TEF3 in each strain was used as the control. The relative quantitation was based on two standard curves for comparisons and the results were given as a ratio [16]. The level of CDR1 mRNA isolated from the wild-type cells in the absence of serum was defined as one. The relative level of mRNA isolated from different strains was normalized accordingly.
###end p 31
###begin title 32
Authors' contributions
###end title 32
###begin p 33
###xml 102 113 102 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1p-RLUC </italic>
YLY designed the study and drafted the manuscript with contribution from HJL. MYT and HIS constructed CDR1p-RLUC and YHL, CGC, JCF and JSW performed experiments.
###end p 33
###begin title 34
Acknowledgements
###end title 34
###begin p 35
We thank Drs. G. Fink, C. Gale, A. Mitchell, H. Nakayama, R. Prasad, and D. Sanglard for strains and plasmids. This work was in part supported by grants 94-2320-B-400-001 and 94-2320-B-009-001 from Nation Science Council and CL-094-PP-05 from National Health Research Institutes.
###end p 35
###begin article-title 36
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida </italic>
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
###end article-title 36
###begin article-title 37
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida </italic>
Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002
###end article-title 37
###begin article-title 38
###xml 42 59 42 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 42 58 <span type="species:ncbi:5476">Candida albicans</span>
Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters
###end article-title 38
###begin article-title 39
###xml 20 37 20 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 20 36 <span type="species:ncbi:5476">Candida albicans</span>
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
###end article-title 39
###begin article-title 40
Mechanisms of antifungal agent resistance
###end article-title 40
###begin article-title 41
###xml 24 41 24 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 24 40 <span type="species:ncbi:5476">Candida albicans</span>
Transcript profiling in Candida albicans reveals new cellular functions for the transcriptional repressors CaTup1, CaMig1 and CaNrg1
###end article-title 41
###begin article-title 42
###xml 42 59 42 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 42 58 <span type="species:ncbi:5476">Candida albicans</span>
CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1
###end article-title 42
###begin article-title 43
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TAC </italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR </italic>
###xml 107 124 107 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR2</italic>
###xml 107 123 <span type="species:ncbi:5476">Candida albicans</span>
TAC 1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2
###end article-title 43
###begin article-title 44
###xml 61 77 61 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 61 77 <span type="species:ncbi:5476">Candida albicans</span>
Influence of human serum on antifungal pharmacodynamics with Candida albicans
###end article-title 44
###begin article-title 45
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
###end article-title 45
###begin article-title 46
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1</italic>
###xml 39 55 39 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 39 55 <span type="species:ncbi:5476">Candida albicans</span>
CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole
###end article-title 46
###begin article-title 47
###xml 46 63 46 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 46 62 <span type="species:ncbi:5476">Candida albicans</span>
N-acetyl-D-glucosamine induces germination in Candida albicans through a mechanism sensitive to inhibitors of cAMP-dependent protein kinase
###end article-title 47
###begin article-title 48
###xml 62 78 62 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans</italic>
###xml 62 78 <span type="species:ncbi:5476">Candida albicans</span>
Induction of germ tube formation by N-acetyl-D-glucosamine in Candida albicans: uptake of inducer and germinative response
###end article-title 48
###begin article-title 49
###xml 73 79 <span type="species:ncbi:4932">yeasts</span>
Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard
###end article-title 49
###begin article-title 50
###xml 30 47 30 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida albicans </italic>
###xml 30 46 <span type="species:ncbi:5476">Candida albicans</span>
Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions
###end article-title 50
###begin article-title 51
###xml 22 29 <span type="species:ncbi:8355">Xenopus</span>
Mesoderm induction in Xenopus is a zygotic event regulated by maternal VegT via TGFbeta growth factors
###end article-title 51
###begin title 52
Figures and Tables
###end title 52
###begin p 53
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fluconazole susceptibility testing</bold>
###xml 163 173 163 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cdr1/cdr1 </italic>
###xml 273 279 <span type="species:ncbi:9913">bovine</span>
Fluconazole susceptibility testing. The inhibition on growth by fluconazole was determined by microdilution method. The wild-type strain (SC5314, squares) and the cdr1/cdr1 mutant cells (DSY448, triangles) were grown in the absence (solid symbols) or presence of 10% fetal bovine serum (open symbols). The optical density (OD) of each well was read at 600 nm after incubated at 35degreesC for 48 hours. The horizontal dotted line represents 50% inhibition and the vertical dotted line refers the inhibition by 0.125 mg/l fluconazole.
###end p 53
###begin p 54
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Construction of <italic>CDR1 </italic>promoter-Renilla luciferase</bold>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RLUC</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">URA3 </italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 438 449 438 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. albicans</italic>
###xml 438 449 <span type="species:ncbi:5476">C. albicans</span>
Construction of CDR1 promoter-Renilla luciferase. The PCR products containing the promoter and the translation initiation site of CDR1 (open box) were introduced in-frame with the sequence encoding luciferase (RLUC, hatched box) into the plasmid pGEM with the wild-type URA3 gene as the selective marker. The LOB 85 plasmid was linearized with EcoRV, transformed, and integrated into the chromosome at the promoter of CDR1 (solid box) in C. albicans.
###end p 54
###begin p 55
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The activity assay of <italic>CDR1 </italic>promoter-Renilla luciferase gene</bold>
###xml 341 347 <span type="species:ncbi:9913">bovine</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
The activity assay of CDR1 promoter-Renilla luciferase gene. The activity of luciferase from control cells (bar 1) was defined as one. The activity of luciferase from cells in the presence of miconazole or sera was normalized accordingly. Bar 1, with neither serum nor miconazole; bar 2, with 100 mug/ml of miconazole; bar 3, with 10% fetal bovine serum; bars 4 and 5, with 10% human serum.
###end p 55
###begin p 56
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDR1 </italic>
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The level of <italic>CDR1 </italic>mRNA</bold>
###xml 402 418 402 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CaNDT80/CaNDT80 </italic>
###xml 438 454 438 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80 </italic>
###xml 474 499 474 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candt80/Candt80::CANDT80 </italic>
###xml 127 133 <span type="species:ncbi:9913">bovine</span>
The level of CDR1 mRNA. Total RNA was isolated from cells in the absence of serum (bars 1, 4, 7), in the presence of 10% fetal bovine serum (bars 2, 5, 8), or in the presence of 5 mM Glu-NAc (bars 3, 6, 9). The level of RNA isolated from the wild-type cells in the absence of serum was defined as one and the relative level of mRNA isolated from different strains was normalized accordingly. Bars 1-3, CaNDT80/CaNDT80 (SC5314); bars 4-6, Candt80/Candt80 (YLO133), bars 7-9, Candt80/Candt80::CANDT80 (YLO137).
###end p 56

